

SYNTHESIS AND CHIRAL SEPARATION OF NEW BENZYLOXY ANALOGUES OF TWO SK CHANNEL-BLOCKING ALKALOIDS: NML AND AG525

Jean-Luc Hayen (1), Donna Pereira Barbon (1), Coralie Herbet (1), Romain Vitello (1), Nikolay Tumanov (2), Johan Wouters (2), Frédéric Kerff (3), Jean-François Liégeois (1)

1) ULiège, CIRM, Laboratory of Medicinal Chemistry, B-4000 Liège, Belgium

2) UNamur, NISM and NARILIS Research institutes, Department of Chemistry, B-5000 Namur, Belgium

3) ULiège, InBios and CIP, Department of Sciences, B-4000 Liège, Belgium

SK (KCa2.1-3) channels are potassium channels opened by an intracellular increase of calcium and are voltage insensitive. Three subtypes, SK1, SK2, and SK3, are expressed in humans. These channels are known to be involved in the medium-duration afterhyperpolarization of the neuronal membrane which follows the action potential, and they contribute to the repolarization of the action potential in atrial cardiomyocytes¹. Blocking these channels could be useful in treating various pathologies like depression or atrial fibrillation^{2,3}.

In the previous work, our team demonstrated that *N*-methyl-laudanosine (NML) is a blocker of SK channels with a micromolar inhibition constant (K_i)⁴. The dimerization of the 6,7-dimethoxy-tetrahydroisoquinoline ring has resulted in the synthesis of 1,3-bis(6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)propane diastereoisomeric mixture (AG525). The first eluted stereoisomer in preparative chiral HPLC, AG525E1, has shown great promise as an SK channel blocker, particularly for targeting central nervous system SK channels⁵. In these studies, a part of the chemical space focused on adding an aromatic group as a substituent in positions 6,7, and 8 of the tetrahydroisoquinoline ring remains unexplored. This work aims to create similar compounds to NML and AG525 by replacing one methoxy group with a benzyloxy one to evaluate the potential of these compounds as ligands for SK channels.

In this study, we synthesized 6-benzyloxy-7-methoxy analogues of these two alkaloids. For this purpose, 6-benzyloxy-7-methoxy-isoquinoline was prepared to get the corresponding Reissert compound, used for synthesizing alkylated isoquinolines. After methylation and reduction of alkylated isoquinolines, the stereoisomers were isolated using a semi-preparative HPLC technique. The absolute configuration of the stereoisomers was subsequently determined by X-ray crystallography.

A biological screening was performed to test affinities of the synthesised compounds on SK2 and SK3 channels using [¹²⁵I]-radiolabelled apamin in a competition binding assay. Interestingly, in preliminary results, (*S,S*)-1,3-bis(6-(benzyloxy)-7-(methoxy)-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)propane displaces 34% or 65% of the radioligand at a concentration of 1 μ M on SK2 and SK3 channels respectively, which is in a similar range than the reference compound (AG525E1).

Shortly, the other benzyloxy analogues will be synthesised and extensive *in vitro* binding and patch-clamp experiments will be conducted on our new synthesized compounds to further characterize their binding affinities and blocking potencies on SK2 and SK3 channels.

References

- 1) Brown, B. M et al. Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels. *Annu Rev Pharmacol Toxicol* 2020, 60, 219–240.
- 2) Rouchet, N et al. SK Channel Blockade Promotes Burst Firing in Dorsal Raphe Serotonergic Neurons. *Eur J Neurosci* 2008, 28 (6), 1108–1115.
- 3) Diness, J. G et al. Inhibition of Small-Conductance Ca²⁺-Activated K⁺ Channels Terminates and Protects against Atrial Fibrillation. *Circ Arrhythm Electrophysiol* 2010, 3 (4), 380–390.
- 4) Scuvée-Moreau, J et al. A New Pharmacological Tool to Investigate the Function of Small-Conductance Ca²⁺-Activated K⁺ Channels. *J Pharmacol Exp Ther* 2002, 302 (3), 1176–1183.
- 5) Graulich, A et al. Bis-Tetrahydroisoquinoline Derivatives: AG525E1, a New Step in the Search for Non-Quaternary Non-Peptidic Small Conductance Ca(2+)-Activated K(+) Channel Blockers. *Bioorg Med Chem Lett* 2008, 18 (11), 3440–3445.